Hookipa, reeling from Roche’s KRAS cull, lays off 30% of workforce, deprioritizes programs

Roche has waved goodbye to one of its KRAS prospects, terminating an alliance with Hookipa Pharma 15 months after betting $25 million on its novel approach to the oncogene. Shortly after receiving the news, Hookipa decided to lay off 30% of its employees and focus on a slimmed-down list of candidates.